967.9K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Marc Grasso | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 03 Mar 2025 | 18,091 | 312,560 (0%) | 0% | 1.5 | 26,547 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 03 Mar 2025 | 40,330 | 2,466,744 (3%) | 0% | 1.5 | 59,176 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 03 Mar 2025 | 16,306 | 332,977 (0%) | 0% | 1.5 | 23,927 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 03 Mar 2025 | 29,073 | 536,142 (0%) | 0% | 1.5 | 42,662 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.52 per share. | 02 Dec 2024 | 14,892 | 349,283 (0%) | 0% | 2.5 | 37,519 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.52 per share. | 02 Dec 2024 | 52,172 | 2,507,074 (3%) | 0% | 2.5 | 131,442 | Common Stock |
| Grasso Marc | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.52 per share. | 02 Dec 2024 | 16,489 | 330,651 (0%) | 0% | 2.5 | 41,542 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 2.52 per share. | 02 Dec 2024 | 26,500 | 565,215 (0%) | 0% | 2.5 | 66,764 | Common Stock |
| Marc Grasso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 216,400 | 347,140 (0%) | 0% | 0 | Common Stock | |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 610,500 | 2,559,246 (3%) | 0% | 0 | Common Stock | |
| Gary Romano | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 184,380 | 364,175 (0%) | 0% | 0 | Common Stock | |
| Saraswati Kenkare-Mitra | President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 300,000 | 591,715 (0%) | 0% | 0 | Common Stock | |
| Marc Grasso | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.88 per share. | 03 Sep 2024 | 7,297 | 130,740 (0%) | 0% | 4.9 | 35,620 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.88 per share. | 03 Sep 2024 | 26,499 | 1,948,746 (2%) | 0% | 4.9 | 129,387 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.88 per share. | 03 Sep 2024 | 8,478 | 179,795 (0%) | 0% | 4.9 | 41,385 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 4.88 per share. | 03 Sep 2024 | 13,926 | 291,715 (0%) | 0% | 4.9 | 67,981 | Common Stock |
| Kristine Yaffe | Director | Sale of securities on an exchange or to another person at price $ 5.06 per share. | 12 Aug 2024 | 5,000 | 67,709 (0%) | 0% | 5.1 | 25,309 | Common Stock |
| Paula Hammond | Director | Sale of securities on an exchange or to another person at price $ 5.06 per share. | 12 Aug 2024 | 10,500 | 60,209 (0%) | 0% | 5.1 | 53,179 | Common Stock |
| Louis J. Lavigne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 35,000 | 70,709 (0%) | 0% | 0 | Common Stock | |
| David M. Wehner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 35,000 | 115,330 (0%) | 0% | 0 | Common Stock | |
| Kristine Yaffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 35,000 | 72,709 (0%) | 0% | 0 | Common Stock | |
| Paula Hammond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 35,000 | 70,709 (0%) | 0% | 0 | Common Stock | |
| Elizabeth A. Garofalo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 35,000 | 61,250 (0%) | 0% | 0 | Common Stock | |
| Marc Grasso | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 03 Jun 2024 | 6,920 | 138,037 (0%) | 0% | 4.8 | 33,208 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 03 Jun 2024 | 25,135 | 1,975,245 (2%) | 0% | 4.8 | 120,618 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 03 Jun 2024 | 8,040 | 188,273 (0%) | 0% | 4.8 | 38,582 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 03 Jun 2024 | 13,206 | 305,641 (0%) | 0% | 4.8 | 63,373 | Common Stock |
| Mark Altmeyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2024 | 41,250 | 41,250 (0%) | 0% | 0 | Common Stock | |
| Altmeyer Mark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2024 | 19,420 | 19,420 | - | - | Stock Option (right to buy) | |
| Marc Grasso | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.92 per share. | 04 Mar 2024 | 5,716 | 144,957 (0%) | 0% | 6.9 | 39,562 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.92 per share. | 04 Mar 2024 | 18,837 | 2,000,380 (2%) | 0% | 6.9 | 130,386 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.92 per share. | 04 Mar 2024 | 6,001 | 196,313 (0%) | 0% | 6.9 | 41,554 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 6.92 per share. | 04 Mar 2024 | 10,169 | 318,847 (0%) | 0% | 6.9 | 70,387 | Common Stock |
| Garofalo A. Elizabeth | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Dec 2023 | 9,459 | 26,250 (0%) | 0% | 0 | Common Stock | |
| Grasso Marc | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.56 per share. | 04 Dec 2023 | 4,574 | 150,673 (0%) | 0% | 5.6 | 25,431 | Common Stock |
| Rosenthal Arnon | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.56 per share. | 04 Dec 2023 | 23,831 | 2,019,217 (2%) | 0% | 5.6 | 132,500 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 5.56 per share. | 04 Dec 2023 | 12,519 | 329,016 (0%) | 0% | 5.6 | 69,606 | Common Stock |
| Romano Gary | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.56 per share. | 04 Dec 2023 | 5,035 | 202,314 (0%) | 0% | 5.6 | 27,995 | Common Stock |
| Louis J. Lavigne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 26,250 | 35,709 (0%) | 0% | 0 | Common Stock | |
| Louis J. Lavigne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,360 | 12,360 | - | - | Stock Option (right to buy) | |
| David M. Wehner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,360 | 12,360 | - | - | Stock Option (right to buy) | |
| David M. Wehner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 26,250 | 80,330 (0%) | 0% | 0 | Common Stock | |
| Tillman U. Gerngross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 26,250 | 2,644,319 (3%) | 0% | 0 | Common Stock | |
| Tillman U. Gerngross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,360 | 12,360 | - | - | Stock Option (right to buy) | |
| Kristine Yaffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,360 | 12,360 | - | - | Stock Option (right to buy) | |
| Kristine Yaffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 26,250 | 35,709 (0%) | 0% | 0 | Common Stock | |
| Paula Hammond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 26,250 | 35,709 (0%) | 0% | 0 | Common Stock | |
| Paula Hammond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,360 | 12,360 | - | - | Stock Option (right to buy) | |
| Elizabeth A. Garofalo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 26,250 | 35,709 (0%) | 0% | 0 | Common Stock | |
| Elizabeth A. Garofalo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,360 | 12,360 | - | - | Stock Option (right to buy) | |
| Marc Grasso | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.90 per share. | 02 Jun 2023 | 1,050 | 33,361 (0%) | 0% | 6.9 | 7,249 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.90 per share. | 02 Jun 2023 | 5,255 | 1,651,095 (2%) | 0% | 6.9 | 36,279 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.90 per share. | 02 Jun 2023 | 2,617 | 102,120 (0%) | 0% | 6.9 | 18,067 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 6.90 per share. | 02 Jun 2023 | 4,092 | 184,149 (0%) | 0% | 6.9 | 28,250 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 42,990 | 1,671,536 (2%) | 0% | 0 | Common Stock | |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 03 Mar 2023 | 15,186 | 1,656,350 (2%) | 0% | 6.2 | 94,428 | Common Stock |
| Marc Grasso | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 02 Mar 2023 | 1,291 | 34,411 (0%) | 0% | 8.3 | 10,739 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 02 Mar 2023 | 5,849 | 1,628,546 (2%) | 0% | 8.3 | 48,651 | Common Stock |
| Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 02 Mar 2023 | 10,124 | 188,241 (0%) | 0% | 8.3 | 84,216 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.32 per share. | 02 Dec 2022 | 3,238 | 104,737 (0%) | 0% | 8.3 | 26,933 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.71 per share. | 02 Dec 2022 | 2,145 | 107,975 (0%) | 0% | 8.7 | 18,679 | Common Stock |
| Robert King | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 14,384 | 14,384 | - | - | Employee Stock Option (right to buy) | |
| Robert King | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 21,576 | 550,871 (0%) | 0% | 0 | Common Stock | |
| Marc Grasso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 35,702 | 35,702 (0%) | 0% | 0 | Common Stock | |
| Marc Grasso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 23,801 | 23,801 | - | - | Employee Stock Option (right to buy) | |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 119,446 | 119,446 | - | - | Employee Stock Option (right to buy) | |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 179,169 | 1,634,395 (2%) | 0% | 0 | Common Stock | |
| Gary Romano | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 20,047 | 110,120 (0%) | 0% | 0 | Common Stock | |
| Gary Romano | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 13,365 | 13,365 | - | - | Employee Stock Option (right to buy) | |
| Saraswati Kenkare-Mitra | President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 80,365 | 198,365 (0%) | 0% | 0 | Common Stock | |
| Saraswati Kenkare-Mitra | President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 53,576 | 53,576 | - | - | Employee Stock Option (right to buy) | |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 10.62 per share. | 02 Sep 2022 | 176 | 529,295 (0%) | 0% | 10.6 | 1,869 | Common Stock |
| Gary Romano | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.62 per share. | 02 Sep 2022 | 2,177 | 90,073 (0%) | 0% | 10.6 | 23,120 | Common Stock |
| Louis J. Lavigne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,459 | 9,459 (0%) | 0% | 0 | Common Stock | |
| Louis J. Lavigne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,918 | 18,918 | - | - | Stock Option (right to buy) | |
| David M. Wehner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,918 | 18,918 | - | - | Stock Option (right to buy) | |
| David M. Wehner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,459 | 54,080 (0%) | 0% | 0 | Common Stock | |
| Tillman U. Gerngross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,459 | 2,618,069 (3%) | 0% | 0 | Common Stock | |
| Tillman U. Gerngross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,918 | 18,918 | - | - | Stock Option (right to buy) | |
| Kristine Yaffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,459 | 9,459 (0%) | 0% | 0 | Common Stock | |
| Kristine Yaffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,918 | 18,918 | - | - | Stock Option (right to buy) | |
| Paula Hammond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,459 | 9,459 (0%) | 0% | 0 | Common Stock | |
| Paula Hammond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,918 | 18,918 | - | - | Stock Option (right to buy) | |
| Elizabeth A. Garofalo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,918 | 18,918 | - | - | Stock Option (right to buy) | |
| Elizabeth A. Garofalo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,459 | 9,459 (0%) | 0% | 0 | Common Stock | |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 8.71 per share. | 02 Jun 2022 | 177 | 529,471 (0%) | 0% | 8.7 | 1,542 | Common Stock |
| Gary Romano | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 369,000 | 369,000 | - | - | Employee Stock Option (right to buy) | |
| Gary Romano | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 92,250 | 92,250 (0%) | 0% | 0 | Common Stock | |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 15.57 per share. | 01 Mar 2022 | 287 | 528,404 (0%) | 0% | 15.6 | 4,468 | Common Stock |
| Marc Grasso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 450,000 | 450,000 | - | - | Employee Stock Option (right to buy) | |
| Saraswati Kenkare-Mitra | President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 59,000 | 118,000 (0%) | 0% | 0 | Common Stock | |
| Saraswati Kenkare-Mitra | President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | |
| Saraswati Kenkare-Mitra | President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 59,000 | 59,000 (0%) | 0% | 0 | Common Stock | |
| Shehnaaz Suliman | President and COO | Sale of securities on an exchange or to another person at price $ 22.33 per share. | 10 Dec 2021 | 8,874 | 102,598 (0%) | 0% | 22.3 | 198,192 | Common Stock |
| Shehnaaz Suliman | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.23 per share. | 10 Dec 2021 | 75,000 | 177,598 (0%) | 0% | 17.2 | 1,292,250 | Common Stock |
| Shehnaaz Suliman | President and COO | Sale of securities on an exchange or to another person at price $ 21.69 per share. | 10 Dec 2021 | 66,126 | 111,472 (0%) | 0% | 21.7 | 1,433,975 | Common Stock |
| Shehnaaz Suliman | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 75,000 | 305,187 | - | - | Employee Stock Option (right to buy) | |
| Shehnaaz Suliman | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 75,000 | 380,187 | - | - | Employee Stock Option (right to buy) | |
| Shehnaaz Suliman | President and COO | Sale of securities on an exchange or to another person at price $ 21.73 per share. | 10 Dec 2021 | 10,898 | 102,598 (0%) | 0% | 21.7 | 236,802 | Common Stock |
| Shehnaaz Suliman | President and COO | Sale of securities on an exchange or to another person at price $ 21.16 per share. | 10 Dec 2021 | 64,102 | 113,496 (0%) | 0% | 21.2 | 1,356,347 | Common Stock |
| Shehnaaz Suliman | President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.23 per share. | 10 Dec 2021 | 75,000 | 177,598 (0%) | 0% | 17.2 | 1,292,250 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 20.09 per share. | 01 Dec 2021 | 250 | 528,691 (0%) | 0% | 20.1 | 5,023 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 15,000 | 667,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 55,000 | 2,137,875 (2%) | 0% | 25 | 1,375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 15,000 | 667,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 15,000 | 652,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 15,000 | 652,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 15,000 | 652,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 55,000 | 2,082,875 (2%) | 0% | 25 | 1,375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Nov 2021 | 15,000 | 667,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 55,000 | 2,247,875 (2%) | 0% | 25 | 1,375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 15,000 | 697,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 15,000 | 697,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 15,000 | 697,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 15,000 | 682,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 15,000 | 682,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 15,000 | 682,500 (0%) | 0% | 25 | 375,000 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 04 Nov 2021 | 55,000 | 2,192,875 (2%) | 0% | 25 | 1,375,000 | Common Stock |
| Robert King | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 5,939 | 528,256 (0%) | 0% | 0 | Common Stock | |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 417,213 | 417,213 | - | - | Employee Stock Option (right to buy) | |
| Elizabeth A. Garofalo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2021 | 33,235 | 33,235 | - | - | Stock Option (right to buy) | |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 22 Sep 2021 | 9,625 | 2,302,875 (2%) | 0% | 25.1 | 241,567 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.10 per share. | 22 Sep 2021 | 5,283 | 2,312,500 (2%) | 0% | 26.1 | 137,890 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.29 per share. | 22 Sep 2021 | 94,717 | 2,317,783 (2%) | 0% | 25.3 | 2,395,298 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.76 per share. | 20 Sep 2021 | 91,954 | 2,520,546 (3%) | 0% | 25.8 | 2,368,542 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.56 per share. | 20 Sep 2021 | 8,462 | 2,412,500 (3%) | 0% | 26.6 | 224,739 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.07 per share. | 20 Sep 2021 | 91,538 | 2,420,962 (3%) | 0% | 26.1 | 2,386,698 | Common Stock |
| Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.33 per share. | 20 Sep 2021 | 8,046 | 2,512,500 (3%) | 0% | 26.3 | 211,849 | Common Stock |
| Kristine Yaffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.10 per share. | 10 Sep 2021 | 2,000 | 2,000 (0%) | 0% | 18.1 | 36,200 | Common Stock |
| Kristine Yaffe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 2,000 | 38,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 09 Aug 2021 | 8,734 | 252,744 (0%) | 0% | 10.1 | 88,563 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 4,525 | 84,450 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 8,734 | 31,250 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 9,691 | 81,000 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.79 per share. | 09 Aug 2021 | 300 | 234,319 (0%) | 0% | 27.8 | 8,337 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 09 Aug 2021 | 22,650 | 234,619 (0%) | 0% | 27.2 | 615,430 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 09 Aug 2021 | 4,525 | 257,269 (0%) | 0% | 17.2 | 77,604 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 09 Aug 2021 | 9,691 | 244,010 (0%) | 0% | 8.2 | 79,079 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 06 Jul 2021 | 30,000 | 264,319 (0%) | 0% | 17.2 | 514,500 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.95 per share. | 06 Jul 2021 | 3,600 | 250,495 (0%) | 0% | 36.0 | 129,433 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.10 per share. | 06 Jul 2021 | 10,224 | 254,095 (0%) | 0% | 35.1 | 358,813 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 10,574 | 88,975 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 11,883 | 39,984 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 7,292 | 90,691 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 30,000 | 99,549 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.32 per share. | 06 Jul 2021 | 17,149 | 234,319 (0%) | 0% | 39.3 | 674,220 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 06 Jul 2021 | 7,700 | 251,468 (0%) | 0% | 38.1 | 293,686 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.41 per share. | 06 Jul 2021 | 4,900 | 259,168 (0%) | 0% | 37.4 | 183,332 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 06 Jul 2021 | 10,574 | 264,068 (0%) | 0% | 17.1 | 181,344 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 06 Jul 2021 | 11,883 | 253,494 (0%) | 0% | 10.1 | 120,494 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 06 Jul 2021 | 7,292 | 241,611 (0%) | 0% | 8.2 | 59,503 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.01 per share. | 06 Jul 2021 | 1,100 | 234,319 (0%) | 0% | 40.0 | 44,016 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.20 per share. | 06 Jul 2021 | 10,495 | 235,419 (0%) | 0% | 39.2 | 411,411 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.55 per share. | 06 Jul 2021 | 3,581 | 245,914 (0%) | 0% | 38.6 | 138,059 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.43 per share. | 06 Jul 2021 | 1,000 | 249,495 (0%) | 0% | 37.4 | 37,434 | Common Stock |
| Robert King | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 02 Jul 2021 | 30,000 | 582,317 (0%) | 0% | 10.1 | 304,200 | Common Stock |
| Robert King | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 02 Jul 2021 | 30,000 | 552,317 (0%) | 0% | 8.2 | 244,800 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 31.14 per share. | 02 Jul 2021 | 60,000 | 522,317 (0%) | 0% | 31.1 | 1,868,400 | Common Stock |
| Robert King | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 30,000 | 120,000 | - | - | Employee Stock Option (right to buy) | |
| Robert King | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 30,000 | 70,000 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 02 Jul 2021 | 1,667 | 80,020 (0%) | 0% | 17.1 | 28,589 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 34.65 per share. | 02 Jul 2021 | 3,334 | 76,686 (0%) | 0% | 34.6 | 115,523 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 18,420 | 14,118 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 11,250 | 10,625 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 31,170 | 48,830 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 1,042 | 13,076 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 1,667 | 47,163 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 625 | 10,000 | - | - | Employee Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 02 Jul 2021 | 18,420 | 145,106 (0%) | 0% | 8.2 | 150,307 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 02 Jul 2021 | 11,250 | 156,356 (0%) | 0% | 10.1 | 114,075 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 02 Jul 2021 | 31,170 | 187,526 (0%) | 0% | 17.2 | 534,566 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 31.14 per share. | 02 Jul 2021 | 90,840 | 96,686 (0%) | 0% | 31.1 | 2,828,758 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 02 Jul 2021 | 20,000 | 76,686 (0%) | 0% | 40.0 | 800,320 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 02 Jul 2021 | 1,042 | 77,728 (0%) | 0% | 8.2 | 8,503 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 02 Jul 2021 | 625 | 78,353 (0%) | 0% | 10.1 | 6,338 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.14 per share. | 01 Jul 2021 | 30,000 | 234,319 (0%) | 0% | 31.1 | 934,200 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 17,326 | 129,549 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.23 per share. | 01 Jul 2021 | 26,726 | 246,993 (0%) | 0% | 22.2 | 594,124 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 01 Jul 2021 | 17,326 | 264,319 (0%) | 0% | 17.2 | 297,141 | Common Stock |
| Louis J. Lavigne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 25,709 | 25,709 | - | - | Stock Option (right to buy) | |
| David M. Wehner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 25,709 | 25,709 | - | - | Stock Option (right to buy) | |
| Tillman U. Gerngross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 25,709 | 25,709 | - | - | Stock Option (right to buy) | |
| Kristine Yaffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 25,709 | 25,709 | - | - | Stock Option (right to buy) | |
| Paula Hammond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 25,709 | 25,709 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.07 per share. | 15 Jun 2021 | 30,000 | 273,719 (0%) | 0% | 22.1 | 661,953 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 12,900 | 56,467 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 4,600 | 51,867 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.18 per share. | 15 Jun 2021 | 4,600 | 273,719 (0%) | 0% | 22.2 | 102,049 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 15 Jun 2021 | 4,600 | 278,319 (0%) | 0% | 10.1 | 46,644 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 15 Jun 2021 | 12,900 | 303,719 (0%) | 0% | 10.1 | 130,806 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 15 Jun 2021 | 17,100 | 290,819 (0%) | 0% | 8.2 | 139,536 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 17,100 | 97,983 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 08 Jun 2021 | 7,292 | 281,011 (0%) | 0% | 8.2 | 59,503 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 11,883 | 42,284 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 7,292 | 115,083 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.83 per share. | 08 Jun 2021 | 800 | 273,719 (0%) | 0% | 20.8 | 16,661 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.89 per share. | 08 Jun 2021 | 2,200 | 274,519 (0%) | 0% | 19.9 | 43,753 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 08 Jun 2021 | 16,175 | 276,719 (0%) | 0% | 19.0 | 307,331 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 08 Jun 2021 | 11,883 | 292,894 (0%) | 0% | 10.1 | 120,494 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 17.77 per share. | 02 Jun 2021 | 1,844 | 126,686 (0%) | 0% | 17.8 | 32,768 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 14,191 | 122,375 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 784 | 54,167 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.14 per share. | 21 May 2021 | 14,975 | 273,719 (0%) | 0% | 18.1 | 271,681 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 21 May 2021 | 784 | 288,694 (0%) | 0% | 10.1 | 7,950 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 21 May 2021 | 14,191 | 287,910 (0%) | 0% | 8.2 | 115,799 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 18 May 2021 | 4,200 | 273,719 (0%) | 0% | 18.0 | 75,786 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 1,300 | 54,951 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 2,900 | 136,566 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 18 May 2021 | 1,300 | 277,919 (0%) | 0% | 10.1 | 13,182 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 18 May 2021 | 2,900 | 276,619 (0%) | 0% | 8.2 | 23,664 | Common Stock |
| Robert King | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 45,000 | 522,317 (0%) | 0% | 0 | Common Stock | |
| Shehnaaz Suliman | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 150,000 | 1,455,226 (1%) | 0% | 0 | Common Stock | |
| Calvin Yu | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 16,000 | 126,686 (0%) | 0% | 0 | Common Stock | |
| Robert Paul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 60,000 | 273,719 (0%) | 0% | 0 | Common Stock | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 07 Apr 2021 | 17,092 | 230,811 (0%) | 0% | 8.2 | 139,471 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 3,125 | 146,875 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 2,083 | 56,251 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 17,092 | 139,466 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.82 per share. | 07 Apr 2021 | 45 | 213,719 (0%) | 0% | 19.8 | 892 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.19 per share. | 07 Apr 2021 | 22,255 | 213,764 (0%) | 0% | 19.2 | 427,158 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 07 Apr 2021 | 3,125 | 236,019 (0%) | 0% | 17.2 | 53,594 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 07 Apr 2021 | 2,083 | 232,894 (0%) | 0% | 10.1 | 21,122 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.85 per share. | 22 Mar 2021 | 24,490 | 219,229 (0%) | 0% | 22.9 | 559,601 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2021 | 13,800 | 156,558 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Mar 2021 | 30,000 | 170,358 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.21 per share. | 22 Mar 2021 | 13,800 | 213,719 (0%) | 0% | 22.2 | 306,498 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 22 Mar 2021 | 13,800 | 227,519 (0%) | 0% | 8.2 | 112,608 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.55 per share. | 22 Mar 2021 | 5,510 | 213,719 (0%) | 0% | 23.6 | 129,774 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 22 Mar 2021 | 30,000 | 243,719 (0%) | 0% | 8.2 | 244,800 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 09 Mar 2021 | 2,083 | 232,894 (0%) | 0% | 10.1 | 21,122 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 2,083 | 58,334 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 17,092 | 200,358 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.12 per share. | 09 Mar 2021 | 19,175 | 213,719 (0%) | 0% | 18.1 | 347,405 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 09 Mar 2021 | 17,092 | 230,811 (0%) | 0% | 8.2 | 139,471 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 17,091 | 217,450 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 2,084 | 60,417 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 09 Feb 2021 | 19,175 | 213,719 (0%) | 0% | 20.8 | 399,055 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 09 Feb 2021 | 2,084 | 232,894 (0%) | 0% | 10.1 | 21,132 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 09 Feb 2021 | 17,091 | 230,810 (0%) | 0% | 8.2 | 139,463 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 25 Jan 2021 | 27,916 | 241,635 (0%) | 0% | 8.2 | 227,795 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 4,166 | 62,501 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 23,142 | 234,541 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 2,084 | 66,667 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 27,916 | 257,683 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 25 Jan 2021 | 27,308 | 213,719 (0%) | 0% | 18 | 491,544 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 25 Jan 2021 | 4,166 | 241,027 (0%) | 0% | 10.1 | 42,243 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 25 Jan 2021 | 23,142 | 236,861 (0%) | 0% | 8.2 | 188,839 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 25 Jan 2021 | 30,000 | 213,719 (0%) | 0% | 18.0 | 540,225 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 25 Jan 2021 | 2,084 | 243,719 (0%) | 0% | 10.1 | 21,132 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 19 Jan 2021 | 27,917 | 241,636 (0%) | 0% | 8.2 | 227,803 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 2,083 | 68,751 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 6,484 | 285,599 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 2,083 | 70,834 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 27,917 | 292,083 | - | - | Employee Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 19 Jan 2021 | 8,567 | 213,719 (0%) | 0% | 18.0 | 154,211 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.12 per share. | 19 Jan 2021 | 30,000 | 213,719 (0%) | 0% | 18.1 | 543,552 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 19 Jan 2021 | 2,083 | 243,719 (0%) | 0% | 10.1 | 21,122 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 19 Jan 2021 | 6,484 | 220,203 (0%) | 0% | 8.2 | 52,909 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 19 Jan 2021 | 2,083 | 222,286 (0%) | 0% | 10.1 | 21,122 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.94 per share. | 15 Jul 2020 | 9,622 | 214,097 (0%) | 0% | 22.9 | 220,729 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.58 per share. | 15 Jul 2020 | 378 | 213,719 (0%) | 0% | 23.6 | 8,913 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.43 per share. | 15 Jun 2020 | 6,091 | 227,628 (0%) | 0% | 29.4 | 179,258 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.90 per share. | 15 Jun 2020 | 3,909 | 223,719 (0%) | 0% | 29.9 | 116,879 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 03 Jun 2020 | 1,043 | 110,986 (0%) | 0% | 31.0 | 32,375 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 32.02 per share. | 03 Jun 2020 | 300 | 110,686 (0%) | 0% | 32.0 | 9,606 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 26.24 per share. | 15 May 2020 | 3,365 | 488,952 (0%) | 0% | 26.2 | 88,298 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.78 per share. | 15 May 2020 | 3,003 | 477,317 (0%) | 0% | 27.8 | 83,423 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 27.02 per share. | 15 May 2020 | 8,632 | 480,320 (0%) | 0% | 27.0 | 233,237 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 15 May 2020 | 5,996 | 235,823 (0%) | 0% | 27 | 161,892 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.78 per share. | 15 May 2020 | 2,104 | 233,719 (0%) | 0% | 27.8 | 58,449 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.15 per share. | 15 May 2020 | 1,900 | 241,819 (0%) | 0% | 26.2 | 49,685 | Common Stock |
| Louis J. Lavigne | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2020 | 19,274 | 19,274 | - | - | Stock Option (right to buy) | |
| David M. Wehner | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2020 | 19,274 | 19,274 | - | - | Stock Option (right to buy) | |
| Tillman U. Gerngross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2020 | 19,274 | 19,274 | - | - | Stock Option (right to buy) | |
| Kristine Yaffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2020 | 19,274 | 19,274 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.27 per share. | 15 Apr 2020 | 10,000 | 243,719 (0%) | 0% | 22.3 | 222,700 | Common Stock |
| Paula Hammond | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2020 | 29,443 | 29,443 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.46 per share. | 13 Mar 2020 | 176 | 253,719 (0%) | 0% | 24.5 | 4,305 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.49 per share. | 13 Mar 2020 | 5,459 | 253,895 (0%) | 0% | 23.5 | 128,232 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.47 per share. | 13 Mar 2020 | 2,884 | 259,354 (0%) | 0% | 22.5 | 64,803 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.57 per share. | 13 Mar 2020 | 1,481 | 262,238 (0%) | 0% | 21.6 | 31,945 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 29.09 per share. | 14 Feb 2020 | 4,668 | 502,649 (0%) | 0% | 29.1 | 135,792 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 29.77 per share. | 14 Feb 2020 | 10,332 | 492,317 (0%) | 0% | 29.8 | 307,584 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.07 per share. | 14 Feb 2020 | 3,000 | 270,719 (0%) | 0% | 29.1 | 87,210 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.74 per share. | 14 Feb 2020 | 7,000 | 263,719 (0%) | 0% | 29.7 | 208,180 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 35.03 per share. | 07 Feb 2020 | 19,900 | 573,918 (0%) | 0% | 35.0 | 697,097 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 35.02 per share. | 06 Feb 2020 | 24,033 | 110,686 (0%) | 0% | 35.0 | 841,636 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 06 Feb 2020 | 1,096 | 126,390 (0%) | 0% | 8.2 | 8,943 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 06 Feb 2020 | 725 | 127,115 (0%) | 0% | 10.1 | 7,352 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 06 Feb 2020 | 2,621 | 124,494 (0%) | 0% | 35 | 91,735 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 06 Feb 2020 | 2,825 | 127,319 (0%) | 0% | 8.2 | 23,052 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.14 per share. | 06 Feb 2020 | 7,400 | 134,719 (0%) | 0% | 10.1 | 75,036 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2020 | 1,096 | 35,363 | - | - | Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2020 | 725 | 29,275 | - | - | Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2020 | 2,825 | 32,538 | - | - | Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2020 | 7,400 | 21,875 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2020 | 10,000 | 320,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.10 per share. | 05 Feb 2020 | 10,000 | 273,719 (0%) | 0% | 32.1 | 321,000 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 05 Feb 2020 | 10,000 | 283,719 (0%) | 0% | 8.2 | 81,600 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 04 Feb 2020 | 63,541 | 125,294 (0%) | 0% | 30.0 | 1,908,772 | Common Stock |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2020 | 13,541 | 36,459 | - | - | Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 04 Feb 2020 | 13,541 | 188,835 (0%) | 0% | 8.2 | 110,495 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 04 Feb 2020 | 16,667 | 593,918 (0%) | 0% | 30 | 500,010 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2020 | 16,667 | 100,000 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 04 Feb 2020 | 100 | 593,818 (0%) | 0% | 35 | 3,500 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 04 Feb 2020 | 16,667 | 610,585 (0%) | 0% | 8.2 | 136,003 | Common Stock |
| David M. Wehner | None | Purchase of securities on an exchange or from another person at price $ 25.00 per share. | 03 Feb 2020 | 20,000 | 44,621 (0%) | 0% | 25 | 500,000 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 30 Jan 2020 | 8,000 | 273,719 (0%) | 0% | 28 | 224,000 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2020 | 8,000 | 330,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 30 Jan 2020 | 8,000 | 281,719 (0%) | 0% | 8.2 | 65,280 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.22 per share. | 23 Jan 2020 | 599 | 273,719 (0%) | 0% | 25.2 | 15,107 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 23 Jan 2020 | 6,000 | 279,719 (0%) | 0% | 8.2 | 48,960 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2020 | 6,000 | 338,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.22 per share. | 23 Jan 2020 | 5,401 | 274,318 (0%) | 0% | 24.2 | 130,812 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 23 Jan 2020 | 14,467 | 593,918 (0%) | 0% | 25.0 | 362,398 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 23 Jan 2020 | 14,467 | 608,385 (0%) | 0% | 8.2 | 118,051 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 25.21 per share. | 23 Jan 2020 | 2,200 | 593,918 (0%) | 0% | 25.2 | 55,462 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 23 Jan 2020 | 2,200 | 596,118 (0%) | 0% | 8.2 | 17,952 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2020 | 14,467 | 116,667 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2020 | 2,200 | 131,134 | - | - | Stock Option (right to buy) | |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 22.01 per share. | 21 Jan 2020 | 14,997 | 507,320 (0%) | 0% | 22.0 | 330,084 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 21 Jan 2020 | 3 | 507,317 (0%) | 0% | 22 | 66 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.67 per share. | 15 Jan 2020 | 10,000 | 273,719 (0%) | 0% | 18.7 | 186,700 | Common Stock |
| Shehnaaz Suliman | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2020 | 550,000 | 550,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 13 Dec 2019 | 10,000 | 283,719 (0%) | 0% | 20.0 | 200,300 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 12 Dec 2019 | 6,810 | 600,728 (0%) | 0% | 8.2 | 55,570 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 12 Dec 2019 | 6,810 | 593,918 (0%) | 0% | 20.1 | 137,069 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2019 | 6,810 | 133,334 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 10 Dec 2019 | 500 | 594,418 (0%) | 0% | 8.2 | 4,080 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2019 | 500 | 140,144 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 10 Dec 2019 | 500 | 593,918 (0%) | 0% | 20.0 | 10,005 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2019 | 5,156 | 142,944 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2019 | 1,500 | 148,100 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 05 Dec 2019 | 2,300 | 593,918 (0%) | 0% | 20.1 | 46,161 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 05 Dec 2019 | 2,300 | 596,218 (0%) | 0% | 8.2 | 18,768 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.02 per share. | 05 Dec 2019 | 5,156 | 593,918 (0%) | 0% | 20.0 | 103,223 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2019 | 2,300 | 140,644 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 05 Dec 2019 | 1,500 | 593,918 (0%) | 0% | 20 | 30,000 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 05 Dec 2019 | 1,500 | 595,418 (0%) | 0% | 8.2 | 12,240 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 05 Dec 2019 | 5,156 | 599,074 (0%) | 0% | 8.2 | 42,073 | Common Stock |
| Calvin Yu | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 18.31 per share. | 03 Dec 2019 | 1,315 | 175,294 (0%) | 0% | 18.3 | 24,078 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 15.92 per share. | 15 Nov 2019 | 7,500 | 522,317 (0%) | 0% | 15.9 | 119,400 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.93 per share. | 15 Nov 2019 | 10,000 | 293,719 (0%) | 0% | 15.9 | 159,300 | Common Stock |
| Robert King | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Arnon Rosenthal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 520,000 | 520,000 | - | - | Stock Option (right to buy) | |
| Calvin Yu | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Sabah Oney | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.68 per share. | 15 Oct 2019 | 10,000 | 301,719 (0%) | 0% | 14.7 | 146,800 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2019 | 4,000 | 346,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 20 Sep 2019 | 4,000 | 311,719 (0%) | 0% | 20 | 80,000 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 20 Sep 2019 | 4,000 | 315,719 (0%) | 0% | 8.2 | 32,640 | Common Stock |
| Sabah Oney | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 20 Sep 2019 | 400 | 593,918 (0%) | 0% | 20 | 8,000 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 20 Sep 2019 | 400 | 594,318 (0%) | 0% | 8.2 | 3,264 | Common Stock |
| Sabah Oney | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2019 | 400 | 149,600 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 16 Sep 2019 | 10,000 | 311,719 (0%) | 0% | 19.1 | 190,800 | Common Stock |
| Robert King | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 19 Aug 2019 | 7,500 | 529,817 (0%) | 0% | 15 | 112,500 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 19 Aug 2019 | 1,084 | 324,803 (0%) | 0% | 8.2 | 8,845 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 19 Aug 2019 | 1,084 | 323,719 (0%) | 0% | 16 | 17,344 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.16 per share. | 19 Aug 2019 | 916 | 324,635 (0%) | 0% | 8.2 | 7,475 | Common Stock |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 19 Aug 2019 | 916 | 323,719 (0%) | 0% | 16 | 14,656 | Common Stock |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2019 | 1,084 | 348,916 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2019 | 916 | 348,000 | - | - | Stock Option (right to buy) | |
| Robert Paul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.19 per share. | 15 Aug 2019 | 10,000 | 323,719 (0%) | 0% | 14.2 | 141,900 | Common Stock |
| Kristine Yaffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2019 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Carl L Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2019 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Louis J. Lavigne | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2019 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| David M. Wehner | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2019 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Tillman U. Gerngross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2019 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 94,075 | 94,075 (0%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 405,925 | 405,925 (0%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 4,282,288 | 4,688,213 (5%) | 6% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 2,029,626 | 6,717,839 (8%) | 2% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 2,280,479 | 8,998,318 (11%) | 3% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 1,012,282 | 10,010,600 (12%) | 1% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 266,437 | 10,277,037 (13%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 11 Feb 2019 | 157,939 | 10,434,976 (13%) | 0% | 19 | 3,000,841 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 992,437 | 1,086,512 (1%) | 1% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 470,374 | 1,556,886 (1%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 528,510 | 2,085,396 (2%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 234,601 | 2,319,997 (2%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 85,295 | 2,405,292 (3%) | 0% | - | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 11 Feb 2019 | 50,561 | 2,455,853 (3%) | 0% | 19 | 960,659 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 11 Feb 2019 | 203,200 | 203,200 (0%) | 0% | 19 | 3,860,800 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 405,925 | 0 | - | - | Series A-1 Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 94,075 | 0 | - | - | Series A-1 Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 4,282,288 | 0 | - | - | Series A-2 Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 992,437 | 0 | - | - | Series A-2 Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 2,029,626 | 0 | - | - | Series B Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 470,374 | 0 | - | - | Series B Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 2,280,479 | 0 | - | - | Series C Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 528,510 | 0 | - | - | Series C Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 1,012,282 | 0 | - | - | Series D Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 234,601 | 0 | - | - | Series D Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 266,437 | 0 | - | - | Series E Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 11 Feb 2019 | 85,295 | 0 | - | - | Series E Preferred Stock | ||
| Louis J. Lavigne | None | 11 Feb 2019 | 10,552 | 0 | - | - | Series E Preferred Stock | ||
| Louis J. Lavigne | None | 11 Feb 2019 | 10,552 | 10,552 (0%) | 0% | - | Common Stock | ||
| David M. Wehner | None | 11 Feb 2019 | 24,621 | 24,621 (0%) | 0% | - | Common Stock | ||
| David M. Wehner | None | 11 Feb 2019 | 24,621 | 0 | - | - | Series E Preferred Stock | ||
| Tillman U. Gerngross | None | 11 Feb 2019 | 52,760 | 2,608,610 (3%) | 0% | - | Common Stock | ||
| Tillman U. Gerngross | None | 11 Feb 2019 | 374,532 | 0 | - | - | Series C Preferred Stock | ||
| Tillman U. Gerngross | None | 11 Feb 2019 | 52,760 | 0 | - | - | Series E Preferred Stock | ||
| Tillman U. Gerngross | None | 11 Feb 2019 | 374,532 | 2,555,850 (3%) | 0% | - | Common Stock |